Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity

Cereblon, a member of the cullin 4 ring ligase complex (CRL4), is the molecular target of the immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide and is required for the antiproliferative activity of these agents in multiple myeloma (MM) and immunomodulatory activity in T cells. Cereblon�...

Descripción completa

Detalles Bibliográficos
Autores principales: Gandhi, Anita K, Mendy, Derek, Waldman, Michelle, Chen, Gengxin, Rychak, Emily, Miller, Karen, Gaidarova, Svetlana, Ren, Yan, Wang, Maria, Breider, Michael, Carmel, Gilles, Mahmoudi, Afshin, Jackson, Pilgrim, Abbasian, Mahan, Cathers, Brian E, Schafer, Peter H, Daniel, Tom O, Lopez-Girona, Antonia, Thakurta, Anjan, Chopra, Rajesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Haematological Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4253085/
https://www.ncbi.nlm.nih.gov/pubmed/24206017
http://dx.doi.org/10.1111/bjh.12622

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4253085/
https://www.ncbi.nlm.nih.gov/pubmed/24206017
http://dx.doi.org/10.1111/bjh.12622

Ejemplares similares